Myopia Control Spectacle Lenses Breakthrough: What the MiYOSMART iQ Trial Means for Your Practice
Myopia Control Spectacle Lenses Breakthrough: What the MiYOSMART iQ Trial Means for Your Practice
A new generation of myopia control spectacle lenses just posted the strongest efficacy data the category has seen. At ARVO 2026, HOYA Vision Care presented 12-month results for MiYOSMART iQ showing no average myopia progression in children as young as 4 — a result that, if it holds up in broader practice, changes the conversation optometrists have with parents about non-pharmaceutical, non-contact-lens myopia control.
For practices that have leaned on orthokeratology or atropine because spectacle-based control felt like the "weaker" option, this trial is worth a close read.
What Actually Happened
HOYA ran a randomized controlled trial across 196 myopic schoolchildren in Hong Kong, aged 4 to 12, comparing MiYOSMART iQ lenses against standard single-vision lenses. The headline numbers:
- Children wearing MiYOSMART iQ averaged a +0.046 diopter change in spherical equivalent refraction over 12 months
- Children in standard single-vision lenses averaged −0.534 diopters over the same period
- The lens halted clinically relevant progression in 9 out of 10 children during the first year of wear
- This is the first time DIMS-based lens technology has demonstrated control efficacy in children as young as 4
Why the Age-4 Result Matters
Most myopia control evidence to date — for ortho-k, atropine, and earlier-generation DIMS lenses — has centered on children aged 6 and up, largely because younger children are harder to fit, harder to monitor, and progress faster, making trials riskier to run. A lens that shows control efficacy at age 4 opens up an earlier intervention window than most practices have previously had any approved tool for.
What's New in the Lens Itself
MiYOSMART iQ builds on the original Defocus Incorporated Multiple Segments (DIMS) technology — already commercially available and clinically validated with around a 52% reduction in progression versus single-vision lenses over two years. The new "iQ" version adds Triple Enhanced Design (DIMS TED), which HOYA describes as refining the segment geometry to increase the defocus signal delivered to the peripheral retina without changing how the lens looks or wears day-to-day.
How This Compares to Other Control Options
| Modality | Typical efficacy (progression reduction) | Daily compliance burden | Age range with strong evidence |
|---|---|---|---|
| MiYOSMART iQ (DIMS TED) | No average progression at 12 months in trial cohort | Low — worn like normal glasses | 4–12 (new data) |
| Original MiYOSMART (DIMS) | ~52% over 2 years | Low — worn like normal glasses | 6–12 |
| Orthokeratology | 40–60% | High — nightly lens care and insertion | 8+ |
| Low-dose atropine (0.01–0.05%) | 30–60%, dose-dependent | Low — daily eye drop | 4+ |
| Outdoor time increase | Modest, supportive only | Behavioral, hard to enforce | All ages |
This table reflects published ranges across modalities and should be read as directional — head-to-head trials between MiYOSMART iQ and ortho-k or atropine haven't been published yet, so direct comparisons remain provisional.
What's Proven vs What's Still Open
It's worth being precise about what this trial does and doesn't establish:
Proven so far:
- The 12-month RCT data is peer-reviewed-trial-grade and was presented at a major clinical meeting (ARVO 2026)
- The effect size (near-zero average progression) is large relative to prior DIMS-generation lenses
- Efficacy was demonstrated in a younger cohort than prior DIMS trials
Still open:
- Long-term data beyond 12 months hasn't been published yet — myopia control studies typically need 2–3 years to assess durability and rebound risk after discontinuation
- The Hong Kong cohort may not generalize directly to other ethnicities and environments without local validation, as has been seen with other myopia interventions
- Real-world compliance and refraction outcomes outside a trial setting (e.g., a child who doesn't wear the glasses consistently) haven't been studied
The Technology Behind the Result
DIMS lenses work differently from standard single-vision lenses. Instead of correcting the entire visual field with one continuous prescription, the lens surface is divided into a central optical zone for clear distance vision and a surrounding ring of hundreds of small, non-correcting segments that apply myopic defocus across the peripheral retina.
Why Peripheral Defocus Matters
The underlying theory — now backed by a substantial body of research across DIMS, ortho-k, and certain contact lens designs — is that the eye's axial growth is regulated locally by signals from the peripheral retina, not just the fovea. When the periphery experiences myopic defocus, the growth signal that drives axial elongation is dampened. DIMS TED appears to refine how consistently that defocus signal is delivered across the segment array, which HOYA credits for the improved 12-month numbers over the original DIMS design.
What Changed Between MiYOSMART and MiYOSMART iQ
The original MiYOSMART has years of real-world data and a well-established ~52% progression reduction at two years. The "iQ" revision doesn't change the lens's appearance, weight, or wear pattern — it's a refinement of segment geometry and optical design, not a new category of product. That matters for practices: existing fitting protocols, frame compatibility, and patient adaptation timelines should carry over largely unchanged.
Timeline to Clinical Availability
This is trial data presented at a clinical conference, not yet a change to product availability in most markets — the underlying MiYOSMART lens family is already commercially available in many regions including Singapore, Malaysia, and much of Asia-Pacific. Practices should expect:
- Now: Conference presentation and peer discussion of the 12-month data (ARVO 2026)
- Near-term: Peer-reviewed journal publication, which typically follows conference presentation by several months
- Medium-term: Updated marketing and clinical literature from HOYA referencing the iQ-specific trial data, and potential expansion of the "iQ" designation across more markets
Optometrists evaluating whether to switch existing MiYOSMART patients to the iQ version, or recommend it for new fits, should watch for the peer-reviewed publication before making it a core part of clinical messaging — conference data is credible but hasn't yet been through full journal peer review.
What This Means for Your Practice
If you're already fitting MiYOSMART for myopia control, this data gives you a stronger evidence base to discuss with parents — particularly for younger patients you might previously have monitored rather than treated, given the lack of strong data at age 4–5.
A few practical implications:
- Earlier referral conversations. A credible non-invasive option for 4-year-olds means "let's wait and monitor" is no longer the only answer for very young myopic patients.
- Parent education shifts. Spectacle-based control has historically been positioned as the lower-efficacy, lower-hassle option compared to ortho-k or atropine. This data narrows that perceived efficacy gap, which changes how you frame the conversation.
- Tracking matters more, not less. Even with strong trial data, individual patients vary. Practices that track axial length and refraction at every visit will be the ones who can tell a parent — with their own data — whether the lens is working for their specific child.
This is also where having a system that makes longitudinal tracking effortless pays off. With CarrotByte, you can log axial length and refraction at each visit, plot progression automatically, and have that chart ready to show parents at the next appointment — turning trial data into a personalized conversation rather than an abstract statistic.
Start tracking myopia progression with CarrotByte →